Nektar Therapeutics and Evommune reported positive Phase II results in atopic dermatitis, delivering data that supported upbeat investor reactions and subsequent financings covered in BioCentury’s equity report. The readouts showed efficacy signals on standard dermatologic endpoints and acceptable tolerability, positioning both companies to advance toward later‑stage studies or partnering discussions. Positive mid‑stage data in atopic dermatitis — a crowded but high‑value dermatology market — can unlock non‑dilutive capital and strategic collaborations; the report also highlights concurrent financings for Immunic, Galecto and Sutro that underline ongoing investor interest in dermatology and immunology.